

Contents lists available at [ScienceDirect](http://ScienceDirect)

## Virology

journal homepage: [www.elsevier.com/locate/yviro](http://www.elsevier.com/locate/yviro)

## Review

## Life of psi: How full-length HIV-1 RNAs become packaged genomes in the viral particles



Malika Kuzembayeva, Kari Dilley, Luca Sardo, Wei-Shau Hu\*

Viral Recombination Section, HIV Drug Resistance Program, National Cancer Institute, Frederick, MD 21702, USA

## ARTICLE INFO

## Article history:

Received 30 December 2013

Returned to author for revisions

3 January 2014

Accepted 24 January 2014

Available online 14 February 2014

## Keywords:

HIV-1

Retrovirus

RNA transcription and processing

Full-length RNA

RNA export

Rev

RRE

RNA dimerization

RNA packaging

Gag

Virus assembly

## ABSTRACT

As a member of the retrovirus family, HIV-1 packages its RNA genome into particles and replicates through a DNA intermediate that integrates into the host cellular genome. The multiple genes encoded by HIV-1 are expressed from the same promoter and their expression is regulated by splicing and ribosomal frameshift. The full-length HIV-1 RNA plays a central role in viral replication as it serves as the genome in the progeny virus and is used as the template for Gag and GagPol translation. In this review, we summarize findings that contribute to our current understanding of how full-length RNA is expressed and transported, *cis*- and *trans*-acting elements important for RNA packaging, the locations and timing of RNA:RNA and RNA:Gag interactions, and the processes required for this RNA to be packaged into viral particles.

Published by Elsevier Inc.

## Contents

The beginning: biogenesis of HIV-1 RNA.....	362
The journey: RNA export and transport.....	363
The rendezvous: RNA partner selection/dimerization and RNA–Gag interaction.....	364
The destination: HIV-1 full-length RNA assembles into virus particles.....	366
Acknowledgments.....	367
References.....	367


## The beginning: biogenesis of HIV-1 RNA

HIV-1 packages its RNA genome into viral particles; upon entering the target cells, the RNA genome is reverse-transcribed into double-stranded DNA, which is then integrated into the cellular genome to form a provirus (reviewed in [Coffin et al., 1997](#); [Freed and Martin, 2013](#)). Integration of viral DNA affords retroviruses the ability to depend on host cell machinery for gene expression including

transcription as well as post-transcriptional processing. The U3, R and U5 regions in the long terminal repeats (LTRs) of the provirus are the *cis*-elements important for the initiation of transcription by RNA polymerase II and for the modification of the RNA molecules (reviewed in [Coffin et al., 1997](#); [Freed and Martin, 2013](#)). Along with the use of host factors to mediate transcription, HIV-1 also encodes its own *trans*-activator of transcription (Tat) for efficient RNA synthesis ([Gaynor, 1995a](#); [Jones and Peterlin, 1994](#)). Tat interacts with cyclin T1/CDK9 and binds to the stem-loop structure at the 5' end of the RNA transcripts called the *trans*-activating response element (TAR); this complex promotes the hyperphosphorylation of RNA polymerase II to ensure efficient elongation of viral transcripts ([Fackler et al., 2001](#); [Hauber and Cullen, 1988](#); [Parada and Roeder,](#)

\* Corresponding author. Tel.: +1 301 846 1250; fax: +1 301 846 6013.

E-mail addresses: [Wei-Shau.Hu@nih.gov](mailto:Wei-Shau.Hu@nih.gov),  
[kuzembayeva13@gmail.com](mailto:kuzembayeva13@gmail.com) (W.-S. Hu).



**Fig. 1.** HIV-1 generates multiple RNA species through splicing. A single promoter from upstream LTR drives HIV-1 transcription. Along with the unspliced full-length transcript several alternatively spliced transcripts are generated depending on the number of splicing events that occur and which splice sites are selected. The dashed lines connect the major splice donor sites to the appropriate splice acceptor. The proteins expressed by these RNA species are indicated on the left.

1996; Rounseville and Kumar, 1992). The absence of Tat has been shown to lead to the accumulation of prematurely terminated transcripts (Adams et al., 1994; Gaynor, 1995b).

Following RNA transcription, HIV-1 transcripts undergo similar processing steps as cellular RNAs including the addition of the 5' cap, cleavage and the polyadenylation of the 3' end. As with transcription, HIV-1 relies on the components of the host spliceosome machinery for efficient splicing to generate various RNA molecules. Some of the HIV-1 RNA transcripts undergo splicing and generate several different RNA species depending on the selection of the splice sites and the number of splicing events that occur (Fig. 1) (Coffin et al., 1997). Fully spliced HIV-1 RNAs accumulate early in the replication cycle and encode the viral regulatory proteins Tat, Rev and Nef (Fig. 1). Singly spliced or partially spliced RNA species encode Env and the accessory proteins Vif, Vpr and Vpu (Fig. 1) (Cullen, 1998). A portion of the HIV-1 RNA transcripts remains unspliced and these full-length HIV-1 RNAs serve two functions: they are used as a template for translation of Gag and GagPol polyproteins, and they are packaged into the virions as the RNA genome of the next generation (Cullen, 2003; Freed and Martin, 2013). HIV replication is therefore dependent upon the efficient transcription, processing, and nuclear export of unspliced, singly spliced and fully spliced derivatives of the primary transcript.


### The journey: RNA export and transport

The export of cellular RNA molecules from the nucleus to the cytoplasm is a tightly regulated process that serves as a key step in the control of eukaryotic gene expression. Proper processing of mRNA is required for the nuclear export (Libri et al., 2002; Maniatis and Reed, 2002) as post-transcriptional processing events, including splicing facilitate the recruitment of protein factors necessary for export (Huang and Steitz, 2005; Lei and Silver, 2002; Moore and Proudfoot, 2009). This requirement for posttranscriptional processing poses a conundrum for retroviruses such as HIV-1 that need to export intron-containing mRNAs including the unspliced full-length RNA and several other partially spliced mRNAs. Therefore, HIV-1 uses a *trans*-acting viral protein, Rev, and a *cis*-acting viral Rev response element (RRE), to facilitate

the export of intron-containing RNAs (Felber et al., 1989; Malim et al., 1989b; Rosen et al., 1988).

Temporal analysis showed that early after HIV-1 infection, only the fully spliced mRNAs encode for Tat, Rev, or Nef are detected in the cytoplasm (Kim et al., 1989). These fully spliced RNA transcripts use the NXF1 pathway for export, which is the pathway used for many cellular mRNAs. Rev is required for the intron-containing RNAs to be exported from the nucleus to the cytoplasm (Kim et al., 1989). In the absence of functional Rev, unspliced and singly spliced RNA transcripts can be detected in the nuclei but are present in the cytoplasm of infected cells at drastically reduced levels (Felber et al., 1989; Hadzopoulou-Cladaras et al., 1989; Kim et al., 1989; Malim et al., 1988).

Rev allows the export of the intron-containing RNAs by acting as a bridge between the viral RNA and the host export machinery. A small nuclear shuttling protein, Rev contains a leucine-rich nuclear export signal (NES) and an arginine-rich RNA binding region (Kjems et al., 1991; Malim et al., 1990, 1989a; Zapp et al., 1991). Rev binds cooperatively to and multimerizes on RRE (Cook et al., 1991; Hadzopoulou-Cladaras et al., 1989; Malim et al., 1990, 1989b; Mann et al., 1994; Tiley et al., 1992). Located in the coding region of Env, RRE is present in all of the full-length and partially spliced HIV-1 transcripts. RRE is highly structured and folds into several stem-loops (Battiste et al., 1996; Daugherty et al., 2010a, 2010b; DiMattia et al., 2010; Hammarskjöld and Rekosh, 2011); the structure of the HIV-1 RRE, which has recently been solved, forms a tree-dimensional "A" shape; the two legs and the distance between them all play a critical role in the Rev-RRE recognition (Fang et al., 2013). In addition to viral RNA, Rev directly interacts with a karyopherin Crm1 (chromosome region maintenance 1, also known as exportin 1 or Xpo1), which is a member of the importin  $\beta$  family of nuclear transport receptors (Fornerod et al., 1997; Nakielnny and Dreyfuss, 1999; Neville et al., 1997). Leptomycin B, a metabolite of *S. Pombe* that specifically inhibits Crm1-mediated nuclear export, can inhibit Rev-dependent export of RNA transcripts (Daelemans et al., 2002; Kudo et al., 1999; Yashiroda and Yoshida, 2003). The Rev-RRE forms an export complex with Crm1 and RanGTP, a small GTPase (Ran) in a GTP-containing form; this export complex is then transported through the nuclear pore (Fig. 2). Studies have shown that Crm1 interacts with several



**Fig. 2.** Nuclear export mechanism of full-length and partially spliced HIV-1 RNA. Viral protein Rev serves as a bridge that recruits Crm1 and RanGTP to intron-containing HIV-1 RNAs by binding to the RRE. The Rev-RRE-Crm1-RanGTP complex moves through the nuclear pore complex (NPC). Once in cytoplasm, RanGap and RanBP1 lead to hydrolysis of Ran-associated GTP into GDP causing the dissociation of the export complex and the release of HIV-1RNA. Although not shown, other host proteins, such as DDX3, may be involved in the nuclear export process (figure not drawn to scale).

nucleoporins such as Nup358 and Nup214, which may facilitate the movement of the export complex through the pore (Bernad et al., 2004; Fornerod et al., 1997). Once in the cytoplasm, Ran GTPase-activating protein 1 (Ran GAP1) and Ran binding protein 1 (Ran BP1) modulate the activity of Ran by hydrolyzing the Ran-associated GTP into GDP, leading to the dissociation of the export complex (Fig. 2).

Recent studies suggest that an array of additional host factors may be involved in the regulation of full-length HIV-1 RNA expression. At this time, the mechanisms of actions of these proteins are not completely understood; some of these factors may act before or during RNA export whereas other factors may act in a more indirect manner such as RNA stabilization. Several DEAD-box RNA helicase proteins have been reported to be important to viral RNA expression and/or export. For example, DDX3 is thought to be required for the export of the Rev/RRE/Crm1/RanGTP complex (Yedavalli et al., 2004). Knockdown of DDX3 blocks the Rev-RRE-dependent Gag/Gag-Pol expression. Given that DDX3 can directly bind to Crm1, it may function by influencing the Crm1 export complex (Yedavalli et al., 2004). Other DEAD-box helicases may also play a role in HIV-1 RNA expression, including DDX1, DDX5, DDX17, and DDX24 although their mechanisms of actions are less understood (Fang et al., 2004; Ma et al., 2008; Naji et al., 2012; Yasuda-Inoue et al., 2013; Zhou et al., 2013). Among these, DDX1 has been reported to facilitate the binding and multimerization of Rev on RRE (Edgcomb et al., 2012; Robertson-Anderson et al., 2011). The nuclear retention of full-length HIV-1 RNA in the absence of Rev is mediated in part by hnRNP A2/B1 (Gordon et al., 2013). Although not directly involved in RNA export, other host proteins have been reported to play a role in full-length HIV-1 RNA expression. For example, analysis of the proteome associated with HIV-1 RNAs identified nuclear matrix protein Matrin 3 (MATR3) in Rev/RRE complexes (Kula et al., 2011), which is thought to stabilize unspliced and partially spliced HIV-1 RNAs (Yedavalli and Jeang, 2011). Peroxisome proliferator-activated receptor-interacting protein with methyltransferase domain (PIMT) can also interact with Rev and lead to hypermethylation the 5' cap of full-length/partially spliced HIV-1 RNA to facilitate their expression (Yedavalli and Jeang, 2010).

Although HIV-1 uses the Crm1 pathway to export its intron-containing RNAs, other retroviruses may use different export pathways. For example, Mason-Pfizer Monkey Virus (MPMV) uses a structured RNA element termed constitutive transport element (CTE) that employs the cellular NXF1/Tap export pathway to avoid nuclear retention of intron-containing RNAs (Bray et al., 1994). This pathway is Crm1-independent, as treatment with Leptomycin B does not inhibit nuclear export of CTE-containing RNAs (Grüter et al., 1998; Otero et al., 1998; Pasquinelli et al., 1997; Saavedra et al., 1997). Though MPMV uses CTE to export its RNAs through a different pathway, CTE alone can functionally replace Rev/RRE during HIV-1 replication (Bray et al., 1994; McBride et al., 1997; Moore et al., 2009; Srinivasakumar et al., 1997; Ward et al., 2009; Wodrich et al., 2000).

Upon entering the cytoplasm, HIV-1 RNA must be transported to subcellular compartments to serve its functions. Interestingly, proper HIV-1 RNA export appears to tie to not only the RNA function in the cytoplasm but also the function of the protein encoded by that RNA. This phenomenon was first observed in modified mouse cells expressing the human cyclin T1 gene which allows for efficient HIV-1 RNA transcription elongation (Bieniasz et al., 1998; Swanson et al., 2004; Wimmer et al., 1999). HIV-1 RNA can be exported and translated in these cells, but the Gag proteins do not target to the plasma membrane properly resulting in an assembly defect (Mariani et al., 2000; Swanson et al., 2004). This defect can be rescued by re-routing the HIV-1 RNA export through the NXF1 pathway by replacing RRE with MPMV CTE (Swanson

et al., 2004) or by supplementing rodent cells with human Crm1 protein (Elinav et al., 2012; Nagai-Fukataki et al., 2011; Okada et al., 2009; Sherer et al., 2011). A similar phenotype was also observed in human cells when HIV-1 RNA was exported using an unknown pathway (Jin et al., 2009). Therefore, RNA export is closely associated with RNA transport and RNA functions. At this time, the precise mechanism of HIV-1 RNA transport in the cytoplasm is not completely understood. For example, it was reported that later during replication after the expression of Gag, HIV-1 full-length RNA and Gag co-traffic using the microtubules to the virion assembly sites (Lehmann et al., 2009; Molle et al., 2009). However, disrupting microtubules by treating the cells with nocodazole does not inhibit HIV-1 virus production (Molle et al., 2009). Therefore, further studies are needed to understand how HIV-1 RNA is transported in the cytoplasm.

### The rendezvous: RNA partner selection/dimerization and RNA-Gag interaction

HIV-1 packages two copies of unspliced, single-stranded, full-length RNA genome into each viral particle (Chen et al., 2009). Both copies of genomic RNA are full-length, and each encodes all of the genetic information needed for viral replication. Packaging two complete RNA genomes provides the opportunity for frequent template switching events during reverse transcription, resulting in the generation of recombinant viruses that are genetically distinct from the two parental viruses (Hu and Temin, 1990a, 1990b; Rhodes et al., 2003). Strand transfer between the two RNA molecules may also act as a rescue mechanism to recover genetic information from an RNA molecule in which the integrity is compromised (Coffin, 1979; Hu and Temin, 1992).


HIV-1 uses the *cis*-acting elements in the viral RNA and the *trans*-acting elements in Gag to achieve specific packaging of the viral RNA genome. The RNA elements important for packaging of HIV-1 genomic RNA have been mapped to the highly conserved and structured 5' untranslated region (5'UTR) and extend into the 5' end of the *gag* coding sequence (Aldovini and Young, 1990; Buchschacher and Panganiban, 1992; Clavel and Orenstein, 1990; Hayashi et al., 1992; Lever et al., 1989; Luban and Goff, 1994, 1991; McBride et al., 1997). The region required for RNA packaging and RNA dimerization overlap in HIV-1; multiple studies reported that the RNA fragments containing the aforementioned region can dimerize *in vitro* (Awang and Sen, 1993; Darlix et al., 1990; Marquet et al., 1991; Sundquist and Heaphy, 1993). The linkage of the 5' ends of the two RNAs from several retroviruses can be visualized in electron micrographs (Bender and Davidson, 1976; Bender et al., 1978; Chien et al., 1980; Dube et al., 1976; Hoglund et al., 1997; Murti et al., 1981). Initially the entire 5' packaging signal was referred to as  $\Psi$  (psi). Following extensive biochemical probing, mutagenesis, structural, phylogenetic and *in silico* analysis of this leader region, elements important for packaging became better defined (Baudin et al., 1993; Clever et al., 1995a; Harrison and Lever, 1992). Among the important elements in the HIV-1 leader that contribute to efficient RNA packaging are four stem loops (SL1, SL2, SL3, SL4) (Clever et al., 1995b; McBride et al., 1997). SL1 displays a GC-rich 6-nt palindromic sequence at the top of its loop called the dimer initiation signal (DIS). SL2 contains the major splice donor (SD) (Purcell and Martin, 1993). SL3, now denoted as  $\psi$  ( $\Psi$ ) is the most conserved region of the leader sequence and contains a GGAG RNA tetraloop that binds NC with high affinity (De Guzman et al., 1998). SL4 is downstream of SL3 and contains the AUG start codon of *gag*; although a documented structure, SL4 may not be present in the RNA competent to dimerize and be packaged (as discussed later). In addition to mediating RNA dimerization and packaging, the 336-nt 5' leader sequence of the

HIV-1 genome also is important for transcription (TAR), splicing (SD), and contains the reverse transcription primer binding (PBS), making it difficult to parse out what direct and indirect effects mutations in this region have on genome packaging. Many studies have linked the TAR hairpin to dimerization and packaging (Clever et al., 1999; Damgaard et al., 2004; Das et al., 1998; McBride et al., 1997). However, once the regulation of Tat/TAR on transcription was replaced with a tetracycline-inducible system, it became apparent that the TAR hairpin is not required for packaging (Das et al., 2007). Further studies confirm that the TAR hairpin as well as the Poly(A) signal are dispensable for RNA dimerization and packaging (Heng et al., 2012; Sakuragi et al., 2007).

Of the RNA elements described above, the DIS in SL1 is able to mediate *in vitro* dimerization of RNA fragments (Laughrea and Jetté, 1994; Muriaux et al., 1995; Paillart et al., 1994; Skripkin et al., 1994). Furthermore, the DIS sequence has proven to be the dominant factor driving RNA dimerization and RNA partner selection *in vivo* (Chen et al., 2009; Chin et al., 2005; Moore et al., 2007). The autocomplementary nature of the DIS supports the initiation of Watson–Crick base pairing between the two HIV-1 RNA

molecules and the generation of a “kissing loop” (Clever et al., 1996; Kieken et al., 2006; Paillart et al., 1997). The most common DIS sequence is GCGCGC in subtype B, and GUGCAC in subtypes A, C and G HIV-1. The differences in the DIS primary sequences have proven to be a major barrier for recombination between two viral subtypes such as subtype B and subtype C HIV-1, reinforcing the role of the DIS in the initiation of RNA dimerization (Chin et al., 2005).

The influence of the DIS sequences on RNA copackaging is strong evidence that the viral RNAs select co-packaged RNA partners (or initiate RNA dimerization) before they are packaged into the viral particles (Chen et al., 2009; Moore et al., 2007). Furthermore, RNA partner selection occurs in the cytoplasm (Moore et al., 2009). Using cells harboring different proviruses and fusing cells at conditions that allow for the mixing of cytoplasmic but not nuclear content, it was shown that RNA dimerization occurs in the cytoplasm of the cell, not the nucleus (Moore et al., 2009). It is of note that RNAs using different export pathways are able to be copackaged, but to a lesser extent compared with RNAs using the same export pathways, suggesting that RNA partner selection in the cytoplasm occurs where the RNA molecules are still at least partially segregated (Moore et al., 2009).



**Fig. 3.** Cis- and trans- factors of HIV-1 RNA packaging. (A) and (B) Two models of the HIV-1 5' leader RNA secondary structures favoring translation (left) or RNA dimerization and packaging (right). AUG start codon of gag (green), DIS (red),  $\Psi$  (purple), U5 (red). (A) Conformation switch of the HIV-1 5' leader RNA proposed by the Berkhout group (Abbink and Berkhout, 2003). In the long distance interaction (LDI) structure (left) the DIS sequence is sequestered through base-pair interactions with the Poly(A). However, in the branched multiple hairpin (BMH) structure (right) the AUG start codon of gag binds the U5 region, exposing the DIS sequence and promoting RNA dimerization and packaging. (B) Conformation switch proposed by the Summers group (Lu et al., 2011). Alternative RNA secondary structures of the HIV-1 5' leader RNA favoring translation (left) in which DIS is base-paired with the U5 region or dimerization and packaging (right) in which the AUG base-pairs with the U5 region the DIS sequence is exposed. (C) Domains of the HIV-1 Gag polyprotein. MA (Matrix), CA (Capsid), SP1 (Spacer 1), NC (Nucleocapsid), SP2 (Spacer 2), p6.



A specific region of the murine leukemia virus (MLV) genome has been identified as necessary and sufficient for RNA packaging because insertion of this sequence can confer the ability of heterologous RNA to be packaged into viral particles (Adam and Miller, 1988; Hibbert et al., 2004). At this time, the necessary and sufficient HIV-1 packaging signal has not been defined. However, within the viral context, deletions have been made to trim down the sequences required for packaging of the HIV-1 genome. A minimal 159-nt RNA sequence that includes SL1–SL3 through the U5:AUG stem, but lacks TAR, Poly(A) and the upper PBS hairpin structure, can dimerize and is competent to bind NC *in vitro* (Heng et al., 2012). In addition, a 144-nt RNA sequence including a segment of sequence that forms the base of the PBS hairpin (but does not include the primer binding site), SL1, SL3 and SL4 proved to be sufficient to mediate intramolecular dimerization when inserted into an ectopic position in the HIV-1 genome, and was defined as the minimal element required for HIV-1 RNA dimerization *in vivo* (Sakuragi et al., 2007).

The HIV-1 RNA packaging signal is recognized by Gag, which is synthesized as a polyprotein that is later processed into six mature proteins: matrix (MA), capsid (CA), SP1, nucleocapsid (NC), SP2, and p6 (Fig. 3C). Of these domains, NC plays the major role for the selective packaging of the HIV-1 RNA genome (Berkowitz et al., 1993; Luban and Goff, 1994). The NC protein contains two CCHC-type zinc knuckle motifs separated by a linker. Mutations of the NC domain including those in the CCHC sequences can cause severe defects in viral RNA packaging (Aldovini and Young, 1990; Dorfman et al., 1993; Gorelick et al., 1990). Furthermore, replacing the NC domain of HIV-1 Gag with the NC domain of MLV, allows this chimeric polyprotein to package MLV RNA genome, and vice versa (Berkowitz et al., 1995; Zhang and Barklis, 1995). However, the specificity of viral RNA packaging cannot always be changed by replacing the NC domain. For example, swapping the NC domains of HIV-1 and mouse mammary tumor virus (MMTV) does not alter the packaging preferences of these viruses (Poon et al., 1998). Containing a basic patch for membrane targeting, the MA domain has also been shown to have nucleic acid binding properties (Cai et al., 2010; Chukkapalli et al., 2010, 2008; Lochrie et al., 1997; Purohit et al., 2001). However, currently there is no evidence supporting that HIV-1MA plays a role in specific packaging of viral genome.

In addition to serving as the RNA genome, full-length HIV-1 RNA also serves as the mRNA template for Gag/GagPol translation (Butsch and Boris-Lawrie, 2000; Dorman and Lever, 2000). It is not well understood how these two functions of viral RNA are balanced. Multiple studies support a model in which two, or more, alternative structures for the HIV-1 RNA leader sequences exist, the two aforementioned RNA functions are carried out by RNA folded into different structures (Baudin et al., 1993; Berkhout and van Wamel, 2000; Berkhout et al., 2001; Huthoff and Berkhout, 2001a, 2001b; Huthoff et al., 2004; Ooms et al., 2004). Berkhout and colleagues have proposed that the 5' end of HIV-1 RNA can fold into two alternative structures: the long distance interaction (LDI) structure or the branched multiple hairpin (BMH) structure (Fig. 3A). In the LDI conformation, the DIS participates in a long-distance interaction with the upstream Poly(A) domain and therefore cannot engage in the "kissing loop" interactions that induce RNA dimerization (Huthoff and Berkhout, 2001a). However, in the BMH conformation, the DIS sequences are exposed, promoting RNA dimerization and packaging. Although, it has been shown that NC may disrupt the LDI conformation and promote RNA dimerization *in vitro*, the existence of the BMH and LDI structures have yet to be shown *in vivo* (Berkhout et al., 2001). A recent model proposed that the RNA conformation that favors translation sequesters the DIS sequence by interaction with part of the U5, not the Poly(A) region, whereas the AUG start codon participates

in base-pairing in the stem of SL4 (Fig. 3A) (Lu et al., 2011). In the alternative structure, the SL4 is lost as the AUG sequences base-pair with part of U5, displacing and exposing the DIS sequence and promoting dimerizations and packaging (Damgaard et al., 2004; Lu et al., 2011; Wilkinson et al., 2008).

It has been shown that MLV has two pools of RNAs, one serves as template for protein translation and the other serves as the RNA genome (Levin and Rosenak, 1976; Levin et al., 1974). Currently, there is no evidence that such division exists in the HIV-1 RNA population (Butsch and Boris-Lawrie, 2000; Dorman and Lever, 2000). In contrast, a *cis* packaging model was proposed in which the Gag polyprotein preferentially packages the RNA template from which it was translated (Poon et al., 2002). However, it was later shown that Gag efficiently packages RNA *in trans* and that *trans*-packaging is the primary mechanism used for HIV-1 RNA packaging (Nikolaitchik et al., 2006).

The precise location where the Gag and RNA genome interaction takes place is currently not known. It was proposed that HIV-1 full-length RNA and Gag first interact and colocalize in the perinuclear region and this complex subsequently traffics through the cytoplasm to the plasma membrane of the cell (Poole et al., 2005). This proposal was challenged later as HIV-1 RNA genome but not Gag was detected at the perinuclear region (Kemler et al., 2010). Using a co-immunoprecipitation assay coupled to membrane flotation, it was shown that HIV-1 RNA can be pulled down with Gag from the cytoplasmic fraction; additionally, the ability to co-precipitate viral RNA does not depend on the ability of Gag to target to the membrane but is stabilized by the Gag–Gag interaction. These experiments suggest that the initial Gag and RNA genome interaction may occur in the cytoplasm (Kutluay and Bieniasz, 2010).

### The destination: HIV-1 full-length RNA assembles into virus particles

To infect a new host, HIV-1 needs to generate new virions, which is a sophisticated process that involves the assembly of the appropriate numbers of viral proteins, viral RNA, host RNA including tRNA, and recruitment of host proteins to facilitate the exit of the newly generated particles from the cell. By directly visualizing the viral RNA content of individual particles, it was found that most HIV-1 particles contain viral genomes; furthermore, two copies of RNAs are packaged into one particle (Chen et al., 2009). Therefore, the packaging of the viral RNA is a tightly regulated process. As mentioned above, the interactions between Gag and RNA elements ensure the specificity of the RNA genome packaging; however, the mechanism by which HIV-1 regulates the packaging of the two copies of RNAs was unknown. Using RNA genomes of different lengths, it was shown that two copies of RNA were packaged regardless whether the genome was 3 kb, 8 kb, or 17 kb, indicating that viral genome packaging is not regulated by the mass of the RNA (Nikolaitchik et al., 2013). It was further shown that if two dimerization signals were present in a single viral RNA, it can form a self-dimer, and only one copy of the self-dimer is packaged (Nikolaitchik et al., 2013). Taken together, these results indicate that HIV-1 RNA genome packaging is regulated by the recognition of one dimeric RNA.

Although controversial at one point, our current understanding is that the major assembly site for HIV-1 is the plasma membrane (Jouvenet et al., 2006; Ono, 2010). Furthermore, these assembly events preferentially take place in discrete domains of the plasma membrane enriched in cholesterol and sphingolipids, known as lipid rafts (Nguyen and Hildreth, 2000; Ono and Freed, 2001; Ono, 2009). The viral protein Gag orchestrates the assembly process including membrane targeting, Gag–Gag and Gag–GagPol multimerization,

recruitment of Env, and the packaging of viral RNA genome (reviewed in Sundquist and Kräusslich, 2012).

The assembly and RNA packaging process have been visualized using total internal reflection fluorescence (TIRF) microscopy. By tagging Gag with a fluorescent protein and monitoring the signal emitted, the kinetics of virus assembly were examined. In these experiments, individual weak fluorescent signals first appeared on the plasma membrane and the intensity of the signals increased with time; eventually, the intensities of these signals reached a plateau and were in the range of those observed in viral particles. The measured assembly time varied but averaged between 5 and 6 min to 8 and 9 min (Ivanchenko et al., 2009; Jouvenet et al., 2008). Gradual increase of Gag signals on the plasma membrane is consistent with the biochemical studies indicating Gag multimerizes extensively on the membrane but not in the cytoplasm (Kutluay and Bieniasz, 2010). The packaging of the viral RNA genome was studied by labeling the RNA with a fluorescently tagged bacteriophage MS2 coat protein which specifically interacts with the MS2 binding sites engineered into the HIV-1 genome. In these experiments, it was observed that viral RNA genomes can reach the plasma membrane even when Gag is not expressed; these RNA signals moved in a dynamic manner and only resided on the membrane for few seconds (Jouvenet et al., 2009). When Gag and RNA were both expressed, RNA signals appeared on the membrane first; weak Gag signals were detected and co-localized with the RNA approximately 4–5 min after the appearance of RNA signal. As the Gag signal intensities increased with time, the lateral mobility of the viral RNA decreased until the completion of the viral particle assembly (Jouvenet et al., 2009). It should be noted that although the RNA signals were detected prior to those of Gag in these experiments, it remains possible that at this time, a few Gag proteins were associated with RNA, but their signal intensity was below the limit of detection. Together these observations suggest that no more than a few Gag molecules bind RNA in the cytoplasm and together they are targeted to the membrane where Gag multimerization proceeds as Gag assembles around the viral RNA genome.

In summary, HIV-1 full-length RNA plays a central role in viral replication. Its complicated journey from the nucleus to the viral particles requires the sophisticated manipulation of cellular functions and dynamic interactions of viral components. There is still much to be learned about the various stages of the life of the full-length HIV-1 RNA, such as host proteins involved in nuclear RNA export, the mechanism of cytoplasmic RNA transport, the relationship between RNA structures and functions, the location(s) where Gag–RNA interaction takes place, and the molecular interactions between Gag and RNA that lead to specific packaging. Future studies will shed light on many of the currently unanswered questions.

## Acknowledgments

We thank Vinay K. Pathak for insightful discussions and suggestions; Olga Nikolaitchik, Krista Delviks-Frankenberry, and Yang Liu for critical reading of the manuscript. This work was funded by the Intramural Research Program of the Center for Cancer Research, NCI and the Intramural AIDS Targeted Antiviral Program, NIH. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.

## References

- Abbink, T.E.M., Berkhout, B., 2003. A novel long distance base-pairing interaction in human immunodeficiency virus type 1 RNA occludes the Gag start codon. *J. Biol. Chem.* 278, 11601–11611.
- Adam, M.A., Miller, A.D., 1988. Identification of a signal in a murine retrovirus that is sufficient for packaging of nonretroviral RNA into virions. *J. Virol.* 62, 3802–3806.
- Adams, M., Sharmeen, L., Kimpton, J., Romeo, J.M., Garcia, J.V., Peterlin, B.M., Groudine, M., Emerman, M., 1994. Cellular latency in human immunodeficiency virus-infected individuals with high CD4 levels can be detected by the presence of promoter-proximal transcripts. *Proc. Natl. Acad. Sci. U. S. A.* 91, 3862–3866.
- Aldovini, A., Young, R.A., 1990. Mutations of RNA and protein sequences involved in human immunodeficiency virus type 1 packaging result in production of noninfectious virus. *J. Virol.* 64, 1920–1926.
- Awang, G., Sen, D., 1993. Mode of dimerization of HIV-1 genomic RNA. *Biochemistry (Mosc.)* 32, 11453–11457.
- Battiste, J.L., Mao, H., Rao, N.S., Tan, R., Muhandiram, D.R., Kay, L.E., Frankel, A.D., Williamson, J.R., 1996. Alpha helix-RNA major groove recognition in an HIV-1 rev peptide-RRE RNA complex. *Science* 273, 1547–1551.
- Baudin, F., Marquet, R., Isel, C., Darlix, J.L., Ehresmann, B., Ehresmann, C., 1993. Functional sites in the 5' region of human immunodeficiency virus type 1 RNA form defined structural domains. *J. Mol. Biol.* 229, 382–397.
- Bender, W., Chien, Y.H., Chattopadhyay, S., Vogt, P.K., Gardner, M.B., Davidson, N., 1978. High-molecular-weight RNAs of AKR, NZB, and wild mouse viruses and avian reticuloendotheliosis virus all have similar dimer structures. *J. Virol.* 25, 888–896.
- Bender, W., Davidson, N., 1976. Mapping of poly(A) sequences in the electron microscope reveals unusual structure of type C oncornavirus RNA molecules. *Cell* 7, 595–607.
- Berkhout, B., van Wamel, J.L., 2000. The leader of the HIV-1 RNA genome forms a compactly folded tertiary structure. *RNA* 6, 282–295.
- Berkhout, B., Vastenhout, N.L., Klasens, B.I., Huthoff, H., 2001. Structural features in the HIV-1 repeat region facilitate strand transfer during reverse transcription. *RNA N. Y.* 7, 1097–1114.
- Berkowitz, R.D., Luban, J., Goff, S.P., 1993. Specific binding of human immunodeficiency virus type 1 gag polypeptide and nucleocapsid protein to viral RNAs detected by RNA mobility shift assays. *J. Virol.* 67, 7190–7200.
- Berkowitz, R.D., Ohagen, A., Hoglund, S., Goff, S.P., 1995. Retroviral nucleocapsid domains mediate the specific recognition of genomic viral RNAs by chimeric Gag polypeptides during RNA packaging in vivo. *J. Virol.* 69, 6445–6456.
- Bernad, R., van der Velde, H., Fornerod, M., Pickersgill, H., 2004. Nup358/RanBP2 attaches to the nuclear pore complex via association with Nup88 and Nup214/CAN and plays a supporting role in CRM1-mediated nuclear protein export. *Mol. Cell. Biol.* 24, 2373–2384.
- Bieniasz, P.D., Grdina, T.A., Bogerd, H.P., Cullen, B.R., 1998. Recruitment of a protein complex containing Tat and cyclin T1 to TAR governs the species specificity of HIV-1 Tat. *EMBO J.* 17, 7056–7065.
- Bray, M., Prasad, Y., Dubay, J.W., Hunter, E., Jeang, K.T., Rekosh, D., Hammarikjöld, M.L., 1994. A small element from the Mason-Pfizer monkey virus genome makes human immunodeficiency virus type 1 expression and replication Rev-independent. *Proc. Natl. Acad. Sci. U. S. A.* 91, 1256–1260.
- Buchschacher, G.L., Panganiban, A.T., 1992. Human immunodeficiency virus vectors for inducible expression of foreign genes. *J. Virol.* 66, 2731–2739.
- Butsch, M., Boris-Lawrie, K., 2000. Translation is not required to generate virion precursor RNA in human immunodeficiency virus type 1-infected T cells. *J. Virol.* 74, 11531–11537.
- Cai, M., Huang, Y., Craigie, R., Clore, G.M., 2010. Structural basis of the association of HIV-1 matrix protein with DNA. *PLoS One* 5, e15675.
- Chen, J., Nikolaitchik, O., Singh, J., Wright, A., Bencsik, C.E., Coffin, J.M., Ni, N., Lockett, S., Pathak, V.K., Hu, W.S., 2009. High efficiency of HIV-1 genomic RNA packaging and heterozygote formation revealed by single virion analysis. *Proc. Natl. Acad. Sci. U. S. A.* 106, 13535–13540.
- Chien, Y.H., Deng, C.T., Chandler, P., Davidson, N., 1980. A method for the isolation of segments from the 5' ends of retrovirus RNA. *Anal. Biochem.* 102, 281–287.
- Chin, M.P., Rhodes, T.D., Chen, J., Fu, W., Hu, W.S., 2005. Identification of a major restriction in HIV-1 intersubtype recombination. *Proc. Natl. Acad. Sci. U. S. A.* 102, 9002–9007.
- Chukkapalli, V., Hogue, I.B., Boyko, V., Hu, W.-S., Ono, A., 2008. Interaction between the human immunodeficiency virus type 1 Gag matrix domain and phosphatidylinositol-(4,5)-bisphosphate is essential for efficient gag membrane binding. *J. Virol.* 82, 2405–2417.
- Chukkapalli, V., Oh, S.J., Ono, A., 2010. Opposing mechanisms involving RNA and lipids regulate HIV-1 Gag membrane binding through the highly basic region of the matrix domain. *Proc. Natl. Acad. Sci. U. S. A.* 107, 1600–1605.
- Clavel, F., Orenstein, J.M., 1990. A mutant of human immunodeficiency virus with reduced RNA packaging and abnormal particle morphology. *J. Virol.* 64, 5230–5234.
- Clever, J., Sasseti, C., Parslow, T.G., 1995a. RNA secondary structure and binding sites for gag gene products in the 5' packaging signal of human immunodeficiency virus type 1. *J. Virol.* 69, 2101–2109.
- Clever, J., Sasseti, C., Parslow, T.G., 1995b. RNA secondary structure and binding sites for gag gene products in the 5' packaging signal of human immunodeficiency virus type 1. *J. Virol.* 69, 2101–2109.
- Clever, J.L., Eckstein, D.A., Parslow, T.G., 1999. Genetic dissociation of the encapsidation and reverse transcription functions in the 5' R region of human immunodeficiency virus type 1. *J. Virol.* 73, 101–109.
- Clever, J.L., Wong, M.L., Parslow, T.G., 1996. Requirements for kissing-loop-mediated dimerization of human immunodeficiency virus RNA. *J. Virol.* 70, 5902–5908.
- Coffin, J.M., 1979. Structure, replication, and recombination of retrovirus genomes: some unifying hypotheses. *J. Gen. Virol.* 42, 1–26.

- Coffin, J.M., Hughes, S.H., Varmus, H.E. (Eds.), 1997. Cold Spring Harbor Laboratory Press.
- Cook, K.S., Fisk, G.J., Hauber, J., Usman, N., Daly, T.J., Rusche, J.R., 1991. Characterization of HIV-1 REV protein: binding stoichiometry and minimal RNA substrate. *Nucleic Acids Res.* 19, 1577-1583.
- Cullen, B.R., 1998. Retroviruses as model systems for the study of nuclear RNA export pathways. *Virology* 249, 203-210.
- Cullen, B.R., 2003. Nuclear mRNA export: insights from virology. *Trends Biochem. Sci.* 28, 419-424.
- Daelemans, D., Afonina, E., Nilsson, J., Werner, G., Kjems, J., De Clercq, E., Pavlakis, G.N., Vandamme, A.-M., 2002. A synthetic HIV-1 Rev inhibitor interfering with the CRM1-mediated nuclear export. *Proc. Natl. Acad. Sci. U. S. A.* 99, 14440-14445.
- Damgaard, C.K., Andersen, E.S., Knudsen, B., Gorodkin, J., Kjems, J., 2004. RNA interactions in the 5' region of the HIV-1 genome. *J. Mol. Biol.* 336, 369-379.
- Darlix, J.L., Gabus, C., Nugeyre, M.T., Clavel, F., Barre-Sinoussi, F., 1990. Cis elements and trans-acting factors involved in the RNA dimerization of the human immunodeficiency virus HIV-1. *J. Mol. Biol.* 216, 689-699.
- Das, A.T., Harwig, A., Vrolijk, M.M., Berkhout, B., 2007. The TAR hairpin of human immunodeficiency virus type 1 can be deleted when not required for Tat-mediated activation of transcription. *J. Virol.* 81, 7742-7748.
- Das, A.T., Klaver, B., Berkhout, B., 1998. The 5' and 3' TAR elements of human immunodeficiency virus exert effects at several points in the virus life cycle. *J. Virol.* 72, 9217-9223.
- Daugherty, M.D., Booth, D.S., Jayaraman, B., Cheng, Y., Frankel, A.D., 2010a. HIV Rev response element (RRE) directs assembly of the Rev homooligomer into discrete asymmetric complexes. *Proc. Natl. Acad. Sci. U. S. A.* 107, 12481-12486.
- Daugherty, M.D., Liu, B., Frankel, A.D., 2010b. Structural basis for cooperative RNA binding and export complex assembly by HIV Rev. *Nat. Struct. Mol. Biol.* 17, 1337-1342.
- De Guzman, R.N., Wu, Z.R., Stalling, C.C., Pappalardo, L., Borer, P.N., Summers, M.F., 1998. Structure of the HIV-1 nucleocapsid protein bound to the SL3 psi-RNA recognition element. *Science* 279, 384-388.
- DiMattia, M.A., Watts, N.R., Stahl, S.J., Rader, C., Wingfield, P.T., Stuart, D.I., Steven, A.C., Grimes, J.M., 2010. Implications of the HIV-1 Rev dimer structure at 3.2 Å resolution for multimeric binding to the Rev response element. *Proc. Natl. Acad. Sci. U. S. A.* 107, 5810-5814.
- Dorfman, T., Luban, J., Goff, S.P., Haseltine, W.A., Gottlinger, H.G., 1993. Mapping of functionally important residues of a cysteine-histidine box in the human immunodeficiency virus type 1 nucleocapsid protein. *J. Virol.* 67, 6159-6169.
- Dorman, N., Lever, A., 2000. Comparison of viral genomic RNA sorting mechanisms in human immunodeficiency virus type 1 (HIV-1), HIV-2, and Moloney murine leukemia virus. *J. Virol.* 74, 11413-11417.
- Dube, S., Kung, H.J., Bender, W., Davidson, N., Ostertag, W., 1976. Size, subunit composition, and secondary structure of the Friend virus genome. *J. Virol.* 20, 264-272.
- Edgcomb, S.P., Carmel, A.B., Naji, S., Ambrus-Aikelin, G., Reyes, J.R., Saphire, A.C.S., Gerace, L., Williamson, J.R., 2012. DDX1 is an RNA-dependent ATPase involved in HIV-1 Rev function and virus replication. *J. Mol. Biol.* 415, 61-74.
- Elinav, H., Wu, Y., Coskun, A., Hryckiewicz, K., Kemler, I., Hu, Y., Rogers, H., Hao, B., Ben Mamoun, C., Poeschla, E., Sutton, R., 2012. Human CRM1 augments production of infectious human and feline immunodeficiency viruses from murine cells. *J. Virol.* 86, 12053-12068.
- Fackler, O.T., Peterlin, B.M., Weis, K., 2001. Lessons from HIV: movement of macromolecules inside the cell. *Curr. Mol. Med.* 1, 1-7.
- Fang, J., Kubota, S., Yang, B., Zhou, N., Zhang, H., Godbout, R., Pomerantz, R.J., 2004. A DEAD box protein facilitates HIV-1 replication as a cellular co-factor of Rev. *Virology* 330, 471-480.
- Fang, X., Wang, J., O'Carroll, I.P., Mitchell, M., Zuo, X., Wang, Y., Yu, P., Liu, Y., Rausch, J.W., Dyba, M.A., Kjems, J., Schwieters, C.D., Seifert, S., Winans, R.E., Watts, N.R., Stahl, S.J., Wingfield, P.T., Byrd, R.A., Le Grice, S.F.J., Rein, A., Wang, Y.-X., 2013. An Unusual Topological Structure of the HIV-1 Rev Response Element. *Cell* 155, 594-605.
- Felber, B.K., Hadzopoulou-Cladaras, M., Cladaras, C., Copeland, T., Pavlakis, G.N., 1989. rev protein of human immunodeficiency virus type 1 affects the stability and transport of the viral mRNA. *Proc. Natl. Acad. Sci. U. S. A.* 86, 1495-1499.
- Fornerod, M., Ohno, M., Yoshida, M., Mattaj, I.W., 1997. CRM1 is an export receptor for leucine-rich nuclear export signals. *Cell* 90, 1051-1060.
- Freed, E.O., Martin, M.A., 2013. HIVs and Their Replication, Field's Virology. Lippincott, Williams, and Wilkins, pp. 1502-1560.
- Gaynor, R.B., 1995a. Regulation of HIV-1 gene expression by the transactivator protein Tat. *Curr. Top. Microbiol. Immunol.* 193, 51-77.
- Gaynor, R.B., 1995b. Regulation of HIV-1 gene expression by the transactivator protein Tat. *Curr. Top. Microbiol. Immunol.* 193, 51-77.
- Gordon, H., Ajamian, L., Valiente-Echeverria, F., Lévesque, K., Rigby, W.F., Moulard, A.J., 2013. Depletion of hnRNP A2/B1 overrides the nuclear retention of the HIV-1 genomic RNA. *RNA Biol.* 10.
- Gorelick, R.J., Nigida, S.M., Bess, J.W., Arthur, L.O., Henderson, L.E., Rein, A., 1990. Noninfectious human immunodeficiency virus type 1 mutants deficient in genomic RNA. *J. Virol.* 64, 3207-3211.
- Grüter, P., Taberner, C., von Kobbe, C., Schmitt, C., Saavedra, C., Bachi, A., Wilm, M., Felber, B.K., Izaurralde, E., 1998. TAP, the human homolog of Mex67p, mediates CTE-dependent RNA export from the nucleus. *Mol. Cell* 1, 649-659.
- Hadzopoulou-Cladaras, M., Felber, B.K., Cladaras, C., Athanassopoulos, A., Tse, A., Pavlakis, G.N., 1989. The rev (trs/art) protein of human immunodeficiency virus type 1 affects viral mRNA and protein expression via a cis-acting sequence in the env region. *J. Virol.* 63, 1265-1274.
- Hammarskjöld, M.-L., Rekosh, D., 2011. A Long-Awaited Structure Is Revealed. *Viruses* 3, 484-492.
- Harrison, G.P., Lever, A.M., 1992. The human immunodeficiency virus type 1 packaging signal and major splice donor region have a conserved stable secondary structure. *J. Virol.* 66, 4144-4153.
- Hauber, J., Cullen, B.R., 1988. Mutational analysis of the trans-activation-responsive region of the human immunodeficiency virus type 1 long terminal repeat. *J. Virol.* 62, 673-679.
- Hayashi, T., Shioda, T., Iwakura, Y., Shibuta, H., 1992. RNA packaging signal of human immunodeficiency virus type 1. *Virology* 188, 590-599.
- Heng, X., Kharytonchyk, S., Garcia, E.L., Lu, K., Divakaruni, S.S., LaCotti, C., Edme, K., Telesnitsky, A., Summers, M.F., 2012. Identification of a minimal region of the HIV-1 5'-leader required for RNA dimerization, NC binding, and packaging. *J. Mol. Biol.* 417, 224-239.
- Hibbert, C.S., Mirro, J., Rein, A., 2004. mRNA molecules containing murine leukemia virus packaging signals are encapsidated as dimers. *J. Virol.* 78, 10927-10938.
- Hoglund, S., Ohagen, A., Goncalves, J., Panganiban, A.T., Gabuzda, D., 1997. Ultrastructure of HIV-1 genomic RNA. *Virology* 233, 271-279.
- Hu, W.S., Temin, H.M., 1990a. Retroviral recombination and reverse transcription. *Science* 250, 1227-1233.
- Hu, W.S., Temin, H.M., 1990b. Genetic consequences of packaging two RNA genomes in one retroviral particle: pseudodiploidy and high rate of genetic recombination. *Proc. Natl. Acad. Sci. U. S. A.* 87, 1556-1560.
- Hu, W.S., Temin, H.M., 1992. Effect of gamma radiation on retroviral recombination. *J. Virol.* 66, 4457-4463.
- Huang, Y., Steitz, J.A., 2005. SRprizes along a Messenger's Journey. *Mol. Cell* 17, 613-615.
- Huthoff, H., Berkhout, B., 2001a. Two alternating structures of the HIV-1 leader RNA. *RNA* 7, 123-157.
- Huthoff, H., Berkhout, B., 2001b. Mutations in the TAR hairpin affect the equilibrium between alternative conformations of the HIV-1 leader RNA. *Nucleic Acids Res.* 29, 2594-2600.
- Huthoff, H., Girard, F., Wijmenga, S.S., Berkhout, B., 2004. Evidence for a base triple in the free HIV-1 TAR RNA. *RNA* N. Y. 10, 412-423.
- Ivanchenko, S., Godinez, W.J., Lampe, M., Kräusslich, H.-G., Eils, R., Rohr, K., Bräuchle, C., Müller, B., Lamb, D.C., 2009. Dynamics of HIV-1 assembly and release. *PLoS Pathog.* 5, e1000652.
- Jin, J., Sturgeon, T., Weisz, O.A., Mothes, W., Montelaro, R.C., 2009. HIV-1 matrix dependent membrane targeting is regulated by Gag mRNA trafficking. *PLoS One* 4, e6551.
- Jones, K.A., Peterlin, B.M., 1994. Control of RNA initiation and elongation at the HIV-1 promoter. *Annu. Rev. Biochem.* 63, 717-743.
- Jouvenet, N., Bieniasz, P.D., Simon, S.M., 2008. Imaging the biogenesis of individual HIV-1 virions in live cells. *Nature* 454, 236-240.
- Jouvenet, N., Neil, S.J.D., Bess, C., Johnson, M.C., Virgen, C.A., Simon, S.M., Bieniasz, P.D., 2006. Plasma membrane is the site of productive HIV-1 particle assembly. *PLoS Biol.* 4, e435.
- Jouvenet, N., Simon, S.M., Bieniasz, P.D., 2009. Imaging the interaction of HIV-1 genomes and Gag during assembly of individual viral particles. *Proc. Natl. Acad. Sci. U. S. A.* 106, 19114-19119.
- Kemler, I., Meehan, A., Poeschla, E.M., 2010. Live-cell coimaging of the genomic RNAs and Gag proteins of two lentiviruses. *J. Virol.* 84, 6352-6366.
- Kieken, F., Paquet, F., Brule, F., Paoletti, J., Lancelot, G., 2006. A new NMR solution structure of the SL1 HIV-1Lai loop-loop dimer. *Nucleic Acids Res.* 34, 343-352.
- Kim, S.Y., Byrn, R., Groopman, J., Baltimore, D., 1989. Temporal aspects of DNA and RNA synthesis during human immunodeficiency virus infection: evidence for differential gene expression. *J. Virol.* 63, 3708-3713.
- Kjems, J., Frankel, A.D., Sharp, P.A., 1991. Specific regulation of mRNA splicing in vitro by a peptide from HIV-1Rev. *Cell* 67, 169-178.
- Kudo, N., Matsumori, N., Taoka, H., Fujiwara, D., Schreiner, E.P., Wolff, B., Yoshida, M., Horinouchi, S., 1999. Leptomycin B inactivates CRM1/exportin 1 by covalent modification at a cysteine residue in the central conserved region. *Proc. Natl. Acad. Sci. U. S. A.* 96, 9112-9117.
- Kula, A., Guerra, J., Knezevich, A., Kleve, D., Myers, M.P., Marcello, A., 2011. Characterization of the HIV-1 RNA associated proteome identifies Matrnx 3 as a nuclear cofactor of Rev function. *Retrovirology* 8, 60.
- Kutluay, S.B., Bieniasz, P.D., 2010. Analysis of the initiating events in HIV-1 particle assembly and genome packaging. *PLoS Pathog.* 6, e1001200.
- Laughrea, M., Jetté, L., 1994. A 19-nucleotide sequence upstream of the 5' major splice donor is part of the dimerization domain of human immunodeficiency virus 1 genomic RNA. *Biochemistry (Mosc.)* 33, 13464-13474.
- Lehmann, M., Milev, M.P., Abrahamyan, L., Yao, X.-J., Pante, N., Moulard, A.J., 2009. Intracellular transport of human immunodeficiency virus type 1 genomic RNA and viral production are dependent on dynein motor function and late endosome positioning. *J. Biol. Chem.* 284, 14572-14585.
- Lei, E.P., Silver, P.A., 2002. Intron status and 3'-end formation control cotranscriptional export of mRNA. *Genes Dev.* 16, 2761-2766.
- Lever, A., Gottlinger, H., Haseltine, W., Sodroski, J., 1989. Identification of a sequence required for efficient packaging of human immunodeficiency virus type 1 RNA into virions. *J. Virol.* 63, 4085-4087.
- Levin, J.G., Grimley, P.M., Ramseur, J.M., Berezsky, I.K., 1974. Deficiency of 60 to 70 S RNA in murine leukemia virus particles assembled in cells treated with actinomycin D. *J. Virol.* 14, 152-161.
- Levin, J.G., Rosenak, M.J., 1976. Synthesis of murine leukemia virus proteins associated with virions assembled in actinomycin D-treated cells: evidence



- for persistence of viral messenger RNA. *Proc. Natl. Acad. Sci. U. S. A.* 73, 1154–1158.
- Libri, D., Dower, K., Boulay, J., Thomsen, R., Rosbash, M., Jensen, T.H., 2002. Interactions between mRNA export commitment, 3'-end quality control, and nuclear degradation. *Mol. Cell. Biol.* 22, 8254–8266.
- Lochrie, M.A., Waugh, S., Pratt, D.G., Clever, J., Parslow, T.G., Polisky, B., 1997. In vitro selection of RNAs that bind to the human immunodeficiency virus type-1 gag polyprotein. *Nucleic Acids Res.* 25, 2902–2910.
- Lu, K., Heng, X., Garyu, L., Monti, S., Garcia, E.L., Kharytonchyk, S., Dorjsuren, B., Kulandaivel, G., Jones, S., Hiremath, A., Divakaruni, S.S., LaCotti, C., Barton, S., Tummillo, D., Hosc, A., Edme, K., Albrecht, S., Telesnitsky, A., Summers, M.F., 2011. NMR detection of structures in the HIV-1 5'-leader RNA that regulate genome packaging. *Science* 334, 242–245.
- Luban, J., Goff, S.P., 1991. Binding of human immunodeficiency virus type 1 (HIV-1) RNA to recombinant HIV-1 gag polyprotein. *J. Virol.* 65, 3203–3212.
- Luban, J., Goff, S.P., 1994. Mutational analysis of cis-acting packaging signals in human immunodeficiency virus type 1 RNA. *J. Virol.* 68, 3784–3793.
- Ma, J., Rong, L., Zhou, Y., Roy, B.B., Lu, J., Abrahamyan, L., Moulard, A.J., Pan, Q., Liang, C., 2008. The requirement of the DEAD-box protein DDX24 for the packaging of human immunodeficiency virus type 1 RNA. *Virology* 375, 253–264.
- Malim, M.H., Böhnlein, S., Hauber, J., Cullen, B.R., 1989a. Functional dissection of the HIV-1 Rev trans-activator – derivation of a trans-dominant repressor of Rev function. *Cell* 58, 205–214.
- Malim, M.H., Hauber, J., Fenrick, R., Cullen, B.R., 1988. Immunodeficiency virus rev trans-activator modulates the expression of the viral regulatory genes. *Nature* 335, 181–183.
- Malim, M.H., Hauber, J., Le, S.Y., Maizel, J.V., Cullen, B.R., 1989b. The HIV-1 rev trans-activator acts through a structured target sequence to activate nuclear export of unspliced viral mRNA. *Nature* 338, 254–257.
- Malim, M.H., Tiley, L.S., McCarn, D.F., Rusche, J.R., Hauber, J., Cullen, B.R., 1990. HIV-1 structural gene expression requires binding of the Rev trans-activator to its RNA target sequence. *Cell* 60, 675–683.
- Maniatis, T., Reed, R., 2002. An extensive network of coupling among gene expression machines. *Nature* 416, 499–506.
- Mann, D.A., Mikaëlian, I., Zimmel, R.W., Green, S.M., Lowe, A.D., Kimura, T., Singh, M., Butler, P.J., Gait, M.J., Karn, J., 1994. A molecular rheostat. Co-operative rev binding to stem I of the rev-response element modulates human immunodeficiency virus type-1 late gene expression. *J. Mol. Biol.* 241, 193–207.
- Mariani, R., Rutter, G., Harris, M.E., Hope, T.J., Kräusslich, H.G., Landau, N.R., 2000. A block to human immunodeficiency virus type 1 assembly in murine cells. *J. Virol.* 74, 3859–3870.
- Marquet, R., Baudin, F., Gabus, C., Darlix, J.L., Mougél, M., Ehresmann, C., Ehresmann, B., 1991. Dimerization of human immunodeficiency virus (type 1) RNA: stimulation by cations and possible mechanism. *Nucleic Acids Res.* 19, 2349–2357.
- McBride, M.S., Schwartz, M.D., Panganiban, A.T., 1997. Efficient encapsidation of human immunodeficiency virus type 1 vectors and further characterization of cis elements required for encapsidation. *J. Virol.* 71, 4544–4554.
- Molle, D., Segura-Morales, C., Camus, G., Berlioz-Torrent, C., Kjems, J., Basyuk, E., Bertrand, E., 2009. Endosomal trafficking of HIV-1 gag and genomic RNAs regulates viral egress. *J. Biol. Chem.* 284, 19727–19743.
- Moore, M.D., Fu, W., Nikolaichik, O., Chen, J., Ptak, R.G., Hu, W.S., 2007. Dimer initiation signal of human immunodeficiency virus type 1: its role in partner selection during RNA copackaging and its effects on recombination. *J. Virol.* 81, 4002–4011.
- Moore, M.D., Nikolaichik, O.A., Chen, J., Hammarskjöld, M.L., Rekosh, D., Hu, W.S., 2009. Probing the HIV-1 genomic RNA trafficking pathway and dimerization by genetic recombination and single virion analyses. *PLoS Pathog.* 5, e1000627.
- Moore, M.J., Proudfoot, N.J., 2009. Pre-mRNA processing reaches back to transcription and ahead to translation. *Cell* 136, 688–700.
- Muriaux, D., Girard, P.M., Bonnet-Mathonière, B., Paoletti, J., 1995. Dimerization of HIV-1 RNA at low ionic strength. An autocomplementary sequence in the 5' leader region is evidenced by an antisense oligonucleotide. *J. Biol. Chem.* 270, 8209–8216.
- Murti, K.G., Bondurant, M., Tereba, A., 1981. Secondary structural features in the 70 S RNAs of Moloney murine leukemia and Rous sarcoma viruses as observed by electron microscopy. *J. Virol.* 37, 411–419.
- Nagai-Fukutaki, M., Ohashi, T., Hashimoto, I., Kimura, T., Hakata, Y., Shida, H., 2011. Nuclear and cytoplasmic effects of human CRM1 on HIV-1 production in rat cells. *Genes Cells Devol. Mol. Cell. Mech.* 16, 203–216.
- Naji, S., Ambrus, G., Cimermančić, P., Reyes, J.R., Johnson, J.R., Filbrandt, R., Huber, M. D., Vesely, P., Krogan, N.J., Yates, J.R., Saphire, A.C., Gerace, L., 2012. Host cell interactome of HIV-1 Rev includes RNA helicases involved in multiple facets of virus production. *Mol. Cell. Proteomics MCP* 11, M111.015313–M111.015313-14.
- Nakiely, S., Dreyfuss, G., 1999. Transport of proteins and RNAs in and out of the nucleus. *Cell* 99, 677–690.
- Neville, M., Stutz, F., Lee, L., Davis, L.L., Rosbash, M., 1997. The importin-beta family member Crm1p bridges the interaction between Rev and the nuclear pore complex during nuclear export. *Curr. Biol.* 7, 767–775.
- Nguyen, D.H., Hildreth, J.E., 2000. Evidence for budding of human immunodeficiency virus type 1 selectively from glycolipid-enriched membrane lipid rafts. *J. Virol.* 74, 3264–3272.
- Nikolaichik, O., Rhodes, T.D., Ott, D., Hu, W.-S., 2006. Effects of mutations in the human immunodeficiency virus type 1 Gag gene on RNA packaging and recombination. *J. Virol.* 80, 4691–4697.
- Nikolaichik, O.A., Dilley, K.A., Fu, W., Gorelick, R.J., Tai, S.-H.S., Soheilian, F., Ptak, R. G., Nagashima, K., Pathak, V.K., Hu, W.-S., 2013. Dimeric RNA recognition regulates HIV-1 genome packaging. *PLoS Pathog.* 9, e1003249.
- Okada, H., Zhang, X., Ben Fofana, I., Nagai, M., Suzuki, H., Ohashi, T., Shida, H., 2009. Synergistic effect of human CycT1 and CRM1 on HIV-1 propagation in rat T cells and macrophages. *Retrovirology* 6, 43.
- Ono, A., 2009. HIV-1 assembly at the plasma membrane: Gag trafficking and localization. *Future Virol.* 4, 241–257.
- Ono, A., 2010. HIV-1 assembly at the plasma membrane. *Vaccine* 28 (Suppl. 2), B55–B59.
- Ono, A., Freed, E.O., 2001. Plasma membrane rafts play a critical role in HIV-1 assembly and release. *Proc. Natl. Acad. Sci. U. S. A.* 98, 13925–13930.
- Ooms, M., Huthoff, H., Russell, R., Liang, C., Berkhout, B., 2004. A riboswitch regulates RNA dimerization and packaging in human immunodeficiency virus type 1 virions. *J. Virol.* 78, 10814–10819.
- Otero, G.C., Harris, M.E., Donello, J.E., Hope, T.J., 1998. Leptomycin B inhibits equine infectious anemia virus Rev and feline immunodeficiency virus rev function but not the function of the hepatitis B virus posttranscriptional regulatory element. *J. Virol.* 72, 7593–7597.
- Paillart, J.C., Marquet, R., Skripkin, E., Ehresmann, B., Ehresmann, C., 1994. Mutational analysis of the bipartite dimer linkage structure of human immunodeficiency virus type 1 genomic RNA. *J. Biol. Chem.* 269, 27486–27493.
- Paillart, J.C., Westhof, E., Ehresmann, C., Ehresmann, B., Marquet, R., 1997. Non-canonical interactions in a kissing loop complex: the dimerization initiation site of HIV-1 genomic RNA. *J. Mol. Biol.* 270, 36–49.
- Parada, C.A., Roeder, R.G., 1996. Enhanced processivity of RNA polymerase II triggered by Tat-induced phosphorylation of its carboxy-terminal domain. *Nature* 384, 375–378.
- Pasquinelli, A.E., Ernst, R.K., Lund, E., Grimm, C., Zapp, M.L., Rekosh, D., Hammarskjöld, M.L., Dahlberg, J.E., 1997. The constitutive transport element (CTE) of Mason-Pfizer monkey virus (MPMV) accesses a cellular mRNA export pathway. *EMBO J.* 16, 7500–7510.
- Poole, E., Strappe, P., Mok, H.P., Hicks, R., Lever, A.M., 2005. HIV-1 Gag–RNA interaction occurs at a perinuclear/cytoplasmic site; analysis by confocal microscopy and FRET. *Traffic* 6, 741–755.
- Poon, D.T., Chertova, E.N., Ott, D.E., 2002. Human immunodeficiency virus type 1 preferentially encapsidates genomic RNAs that encode Pr55(Gag): functional linkage between translation and RNA packaging. *Virology* 293, 368–378.
- Poon, D.T., Li, G., Aldovini, A., 1998. Nucleocapsid and matrix protein contributions to selective human immunodeficiency virus type 1 genomic RNA packaging. *J. Virol.* 72, 1983–1993.
- Purcell, D.F., Martin, M.A., 1993. Alternative splicing of human immunodeficiency virus type 1 mRNA modulates viral protein expression, replication, and infectivity. *J. Virol.* 67, 6365–6378.
- Purohit, P., Dupont, S., Stevenson, M., Green, M.R., 2001. Sequence-specific interaction between HIV-1 matrix protein and viral genomic RNA revealed by in vitro genetic selection. *RNA* 7, 576–584.
- Rhodes, T., Wargo, H., Hu, W.S., 2003. High rates of human immunodeficiency virus type 1 recombination: near-random segregation of markers one kilobase apart in one round of viral replication. *J. Virol.* 77, 11193–11200.
- Robertson-Anderson, R.M., Wang, J., Edgcomb, S.P., Carmel, A.B., Williamson, J.R., Millar, D.P., 2011. Single-molecule studies reveal that DEAD box protein DDX1 promotes oligomerization of HIV-1 Rev on the Rev response element. *J. Mol. Biol.* 410, 959–971.
- Rosen, C.A., Terwilliger, E., Dayton, A., Sodroski, J.G., Haseltine, W.A., 1988. Intragenic cis-acting art gene-responsive sequences of the human immunodeficiency virus. *Proc. Natl. Acad. Sci. U. S. A.* 85, 2071–2075.
- Rounseville, M.P., Kumar, A., 1992. Binding of a host cell nuclear protein to the stem region of human immunodeficiency virus type 1 trans-activation-responsive RNA. *J. Virol.* 66, 1688–1694.
- Saavedra, C., Felber, B., Izaurralde, E., 1997. The simian retrovirus-1 constitutive transport element, unlike the HIV-1 RRE, uses factors required for cellular mRNA export. *Curr. Biol.* 7, 619–628.
- Sakuragi, J., Sakuragi, S., Shioda, T., 2007. Minimal region sufficient for genome dimerization in the human immunodeficiency virus type 1 virion and its potential roles in the early stages of viral replication. *J. Virol.* 81, 7985–7992.
- Sherer, N.M., Swanson, C.M., Hué, S., Roberts, R.G., Bergeron, J.R.C., Malim, M.H., 2011. Evolution of a species-specific determinant within human CRM1 that regulates the post-transcriptional phases of HIV-1 replication. *PLoS Pathog.* 7, e1002395.
- Skripkin, E., Paillart, J.C., Marquet, R., Ehresmann, B., Ehresmann, C., 1994. Identification of the primary site of the human immunodeficiency virus type 1 RNA dimerization in vitro. *Proc. Natl. Acad. Sci. U. S. A.* 91, 4945–4949.
- Srinivasakumar, N., Chazal, N., Helga-Maria, C., Prasad, S., Hammarskjöld, M.L., Rekosh, D., 1997. The effect of viral regulatory protein expression on gene delivery by human immunodeficiency virus type 1 vectors produced in stable packaging cell lines. *J. Virol.* 71, 5841–5848.
- Sundquist, W.L., Heaphy, S., 1993. Evidence for interstrand quadruplex formation in the dimerization of human immunodeficiency virus 1 genomic RNA. *Proc. Natl. Acad. Sci. U. S. A.* 90, 3393–3397.
- Sundquist, W.L., Kräusslich, H.-G., 2012. HIV-1 assembly, budding, and maturation. *Cold Spring Harb. Perspect. Med.* 2, a006924.
- Swanson, C.M., Puffer, B.A., Ahmad, K.M., Doms, R.W., Malim, M.H., 2004. Retroviral mRNA export elements regulate protein function and virion assembly. *EMBO J.* 23, 2632–2640.
- Tiley, L.S., Malim, M.H., Tewary, H.K., Stockley, P.G., Cullen, B.R., 1992. Identification of a high-affinity RNA-binding site for the human immunodeficiency virus type 1 Rev protein. *Proc. Natl. Acad. Sci. U. S. A.* 89, 758–762.
- Ward, A.M., Rekosh, D., Hammarskjöld, M.-L., 2009. Trafficking through the Rev/RRE pathway is essential for efficient inhibition of human immunodeficiency



- virus type 1 by an antisense RNA derived from the envelope gene. *J. Virol.* 83, 940–952.
- Wilkinson, K.A., Gorelick, R.J., Vasa, S.M., Guex, N., Rein, A., Mathews, D.H., Giddings, M.C., Weeks, K.M., 2008. High-throughput SHAPE analysis reveals structures in HIV-1 genomic RNA strongly conserved across distinct biological states. *PLoS Biol.* 6, e96.
- Wimmer, J., Fujinaga, K., Taube, R., Cujec, T.P., Zhu, Y., Peng, J., Price, D.H., Peterlin, B. M., 1999. Interactions between Tat and TAR and human immunodeficiency virus replication are facilitated by human cyclin T1 but not cyclins T2a or T2b. *Virology* 255, 182–189.
- Wodrich, H., Schambach, A., Kräusslich, H.G., 2000. Multiple copies of the Mason-Pfizer monkey virus constitutive RNA transport element lead to enhanced HIV-1 Gag expression in a context-dependent manner. *Nucleic Acids Res.* 28, 901–910.
- Yashiroda, Y., Yoshida, M., 2003. Nucleo-cytoplasmic transport of proteins as a target for therapeutic drugs. *Curr. Med. Chem.* 10, 741–748.
- Yasuda-Inoue, M., Kuroki, M., Ariumi, Y., 2013. Distinct DDX DEAD-box RNA helicases cooperate to modulate the HIV-1 Rev function. *Biochem. Biophys. Res. Commun.* 434, 803–808.
- Yedavalli, V.S.R.K., Jeang, K.-T., 2010. Trimethylguanosine capping selectively promotes expression of Rev-dependent HIV-1 RNAs. *Proc. Natl. Acad. Sci. U. S. A.* 107, 14787–14792.
- Yedavalli, V.S.R.K., Jeang, K.-T., 2011. Matr3 is a co-factor for HIV-1 Rev in regulating post-transcriptional viral gene expression. *Retrovirology* 8, 61.
- Yedavalli, V.S.R.K., Neuveut, C., Chi, Y.-H., Kleiman, L., Jeang, K.-T., 2004. Requirement of DDX3 DEAD box RNA helicase for HIV-1 Rev-RRE export function. *Cell* 119, 381–392.
- Zapp, M.L., Hope, T.J., Parslow, T.G., Green, M.R., 1991. Oligomerization and RNA binding domains of the type 1 human immunodeficiency virus Rev protein: a dual function for an arginine-rich binding motif. *Proc. Natl. Acad. Sci. U. S. A.* 88, 7734–7738.
- Zhang, Y., Barklis, E., 1995. Nucleocapsid protein effects on the specificity of retrovirus RNA encapsidation. *J. Virol.* 69, 5716–5722.
- Zhou, X., Luo, J., Mills, L., Wu, S., Pan, T., Geng, G., Zhang, J., Luo, H., Liu, C., Zhang, H., 2013. DDX5 facilitates HIV-1 replication as a cellular co-factor of Rev. *PLoS One* 8, e65040.